Rhenman & Partners Asset Management AB Acquires 6,750 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Rhenman & Partners Asset Management AB lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 39.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,750 shares of the company's stock after buying an additional 6,750 shares during the quarter. Rhenman & Partners Asset Management AB owned about 0.08% of Krystal Biotech worth $3,721,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in shares of Krystal Biotech in the 3rd quarter worth $40,000. Avanza Fonder AB acquired a new position in shares of Krystal Biotech during the 4th quarter worth about $119,000. KBC Group NV increased its stake in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after acquiring an additional 297 shares during the last quarter. Blue Trust Inc. raised its position in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after acquiring an additional 433 shares during the period. Finally, US Bancorp DE boosted its stake in Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on KRYS shares. HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and an average price target of $220.00.

Remove Ads

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Krystal Biotech Price Performance

NASDAQ:KRYS traded down $8.19 during trading hours on Thursday, reaching $159.97. 157,767 shares of the stock were exchanged, compared to its average volume of 293,668. The stock has a market cap of $4.61 billion, a PE ratio of 53.43 and a beta of 0.75. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The firm has a 50 day moving average of $173.85 and a 200 day moving average of $172.48.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the firm earned $0.30 earnings per share. The firm's revenue for the quarter was up 116.4% compared to the same quarter last year. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).